# EMPAGLIFLOZIN; LINAGLIPTIN
> **ANDA212366** · Abbreviated New Drug Application (Generic) · Sponsor: ALKEM LABS LTD · Approved 2022-08-09
## Drug
- **FDA Application Number:** ANDA212366
- **Application type:** Abbreviated New Drug Application (Generic)
- **Brand name:** EMPAGLIFLOZIN; LINAGLIPTIN
- **Generic name:** Empagliflozin
- **Active ingredients:** EMPAGLIFLOZIN; LINAGLIPTIN
- **Dosage form:** TABLET
- **Route:** ORAL
- **Marketing status:** None (Tentative Approval)
- **Sponsor:** ALKEM LABS LTD
- **First approval:** 2022-08-09
## Source
- [Drugs@FDA application overview](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212366)
---
*AI Analytics · CC0 1.0*